Cochlear’s biggest woe in an earnings downgrade relates to developed markets – notably the US which accounts for more than ...

Cochlear also said that trading conditions for implants in developed markets have been softer-than-expected, while the fourth ...

Cochlear reduces its FY26 earnings guidance amid softer implant sales, ongoing challenges in key markets, and a focus on long ...

The medical device manufacturer has delivered a bitter pill for shareholders. The post Why are Cochlear shares down 36% today ...

The global Artificial Organs and Bionics Market is expected to witness substantial growth, projected to reach US$ 50.7 billion by 2030 ...

A bruising two-day stretch for the S&P/ASX 200 Health Care Index has underscored growing fragility in the sector, with ...

Investing.com-- Shares of Cochlear Ltd (ASX:COH) slumped to a 10-year low on Wednesday after the company cut its full-year ...

Investors today birched Cochlear shares by close to 40% after a radical earnings update – their worst fall in 30 years.

Despite bad news on the earnings front this week, Cochlear shares could still deliver upside. The post How high could Cochlear shares bounce back? Brokers disagree appeared first on The Motley Fool ...

Cochlear Ltd has updated its trading performance, reducing its FY26 earnings guidance to A$290-330 million. The company anticipates a 2-6% sales growth in the second half, in constant currency.

Envoy Medical Inc, a hearing health company pioneering fully implanted hearing solutions, announced that all 56 patients implanted and enrolled in its pivotal clinical trial evaluating the fully ...

Cochlear Ltd shares have suffered their steepest one-day fall since listing in 1995, plunging around 40% after slashing FY26 ...